Alithea Bio
Description
Alithea Bio is a biotechnology company developing innovative solutions in immunopeptidomics to accelerate the discovery of novel therapeutic targets and advance personalized immunotherapy.
Our technology focuses on the immunopeptidome—the collection of peptides presented on the surface of cells and recognized by the immune system. These peptides provide valuable insights into disease biology and can reveal therapeutic targets that are difficult to identify through conventional approaches.
Alithea Bio is developing technologies designed to make immunopeptidomics more efficient, scalable, and accessible, addressing key challenges in sample preparation and analysis. By enabling researchers and biotechnology companies to generate high-quality immunopeptidomic data more effectively, we aim to accelerate target discovery and drug development.
Our vision is to unlock the potential of the immunopeptidome for precision medicine, supporting the development of more targeted therapies and next-generation immunotherapies, particularly in oncology and other areas where the immune system plays a central role.
Alithea Bio operates at the intersection of biotechnology, proteomics, immunology, and precision medicine, with the ambition to provide enabling technologies that transform how therapeutic targets are discovered and validated.
